SG3 Management’s Voyager Therapeutics VYGR Stock Holding History

SG3 Management’s Portfolio VYGR Stock Details VYGR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-3,000	Closed	-$57K	–	531
2019 Q1	$57K	Buy	+3,000	New	+$39.1K	0.01%	269

Other funds holding VYGR

TGI

TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SG3 Management's VYGR Position: Q2 2019 in Review

SG3 Management sold out of Voyager Therapeutics (VYGR) in Q2 2019, closing a stake of 3,000 shares — an estimated $57K sold.

SG3 Management first reported a position in VYGR in Q1 2019 and held it in 1 quarter. The position peaked at $57K in Q1 2019. 125 funds tracked by Wall St. Rank hold VYGR as of Q2 2019.

SG3 Management reported no remaining Voyager Therapeutics position as of Q2 2019 after selling out during the quarter.
SG3 Management sold 3,000 Voyager Therapeutics shares in Q2 2019, an estimated $57K.
SG3 Management first reported a position in Voyager Therapeutics in Q1 2019 and held it in 1 quarter.
SG3 Management's Voyager Therapeutics position peaked at $57K in Q1 2019.
125 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q2 2019.

Based on SG3 Management's 13F filing for Q2 2019, filed 9 Aug 2019.